Worldwide Prescription Drug Sales in 2024: part 1 of 2 Top 10 Companies P昀椀zer returns to top spot for worldwide sales of prescription ranking between 2018 and 2024 with an impressive 10.8% CAGR. drugs in 2024. Bristol-Myers Squibb is unlikely to be outside the top 10 for too ® 昀椀nds long however, as on January 3rd, 2019, the company announced As the top three continue to battle it out, EvaluatePharma that P昀椀zer has once again pushed ahead of Novartis and Roche a $74bn acquisition of Celgene that is yet to complete. for the Worldwide Prescription Drug Sales number one spot in AstraZeneca has also shown impressive 7.7% CAGR, long promised 2024. Novartis is also due to jump up to the number two spot by CEO Pascal Soriot, due to breakthroughs in the Chinese market after exhibiting 2.3% CAGR between 2018-24 as opposed to and high sales of its oncology products Tagrisso and Lynparza, Roche’s 0.8% CAGR. rather than M&A. Bristol-Myers Squibb has fallen out of the top 10 largely due to Only Takeda and AstraZeneca are able to increase market share loss of Opdivo market-share to Keytruda and being beaten to between 2018 and 2024. The Top 10 Pharma companies showed the mega-merger table by Takeda with its acquisition of Shire in -6.6% market share growth overall, with Roche alone contributing January 2019. As a result, Takeda leaps up seven places in the -1.4% to that 昀椀gure. Figure 3: Worldwide Prescription Drug Sales in 2024: Top 10 Companies Source: EvaluatePharma, May 2019 60.0 Sales ($bn) +20% 51.2 Ranking Change 2018-24 +0 49.8 +18% +1 46.7 45.8 50.0 -1 +0 42.5 +16% +0 40.7 38.7 +0 +1 +14% 40.0 35.0 32.3 -1 32.2 +12% +7 +2 30.0 +10.8% +10% +7.7% +8% 20.0 +6% CAGR 2018-2024 (%) +4.0% +2.1% +2.3% +2.8% +2.2% +2.5% +4% WW Prescription Drug Sales ($bn)10.0 +1.4% +0.8% +2% 0.0 +0% Pfizer Novartis Roche Johnson & Merck Sanofi Glaxo- AbbVie Takeda AstraZeneca Johnson & Co SmithKline ® 10 EvaluatePharma World Preview 2019 Copyright © 2019 Evaluate Ltd. All rights reserved.